Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Novartis AG (NYSE:NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44.…
Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023
Edwards Lifesciences Corp (NYSE:EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61.…
Li Auto Posts 23.4% Growth In January Deliveries
Li Auto Inc (NASDAQ:LI) said it delivered 15,141 vehicles in January 2023, a 23.4% increase year-on-year. The cumulative deliveries of Li…
‘Big Short’ Fame Michael Burry’s ‘Sell’ Tweet Causes Social Media Furor
‘The Big Short’ investor Michael Burry has again caused a social media furor with a one-word tweet: ‘Sell.’
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors’ Attention Today
Major Wall Street indices closed over 1% higher on Tuesday, led by upbeat corporate earnings and expectations that the Federal Reserve will slow down its rate hike pace as the centr
Jack Dorsey Hails Twitter Rival’s Listing On Apple, Google App Stores: ‘Milestone For Open Protocols’
Jack Dorsey says the listing of Nostr on the app stores run by Apple Inc and Alphabet Inc's Google is a “milestone” for open protocols.
The Rise Of Artificial Intelligence In Movies: How The Tom Cruise Deepfake Company Is Helping
Artificial intelligence could go down as one of the most talked about items in 2023, thanks in large part to ChatGPT and its parent company OpenAI.
Mesoblast Says Resumbits Biologic License Application To FDA For Remestemcel-L In Children With With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action
Assay Identifies High-Potency Product Lots Associated with Enhanced Survival
New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality
Pushing Rivalry Aside: Elon Musk And Jeff Bezos Agree On How Good This Streaming Show Is
A rivalry between two of the richest people in the world has escalated over the years due to their respective space companies.
Thinkorswim Transitions To Charles Schwab Later This Year: A Look at What’s New And Improved
TD Ameritrade's thinkorswim platform will transition to Charles Schwab Corporation (NYSE: SCHW) later in 2023, according to a Tuesday announcement.